| 2023 | 2022 | 2021 | ||||
|---|---|---|---|---|---|---|
| Revenue | 1,8 M € | +96.2% | 925,9 k € | +152.6% | 366,6 k € | |
| EBITDA | -2,5 M € | +39.8% | -4,1 M € | -298.4% | -1,0 M € | |
| Operating profit | -3,2 M € | +36.5% | -5,1 M € | -120.5% | -2,3 M € | |
| Profit/loss | -3,0 M € | +35.7% | -4,7 M € | -148.5% | -1,9 M € | |
| Equity | 5,3 M € | +102.2% | 2,6 M € | +49.2% | 1,8 M € | |
| Total assets | 7,5 M € | +42.4% | 5,3 M € | +67.6% | 3,1 M € | |
| Cash | 716,0 k € | -80.1% | 3,6 M € | +1464.7% | 229,9 k € | |
| Debts | 1,7 M € | -28.3% | 2,3 M € | +161.8% | 897,0 k € | |
| Staff | 8,2 | 12,1 | 4,1 | |||
Public limited company · Charleroi · incorporated on 02/03/2020 · 8,2 ETP
Company — Opening of bankruptcy.
Public limited company loss-making in the latest fiscal year. Cash position declining (-80.1%).
Solid counterparty for a standard engagement.
UNIZIMA is a Public limited company incorporated in 2020. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Charleroi. It employs on average 8,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette